Fri Aug 4 16:36:36 2006
Complete replication of hepatitis C virus in cell culture
Lindenbach BD, Evans MJ, Syder AJ, et al.
SCIENCE 309 (5734): 623-626 JUL 22 2005
and the citing papers
stopwords, and 2-character and smaller words are excluded, Word count: 639, All words count: 954
Grand TLCS: 116, Grand TGCS: 195| View: Overview | Sorted by word. |
Page 1 of 2: [ 1 2 ]
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 1 | ABUSE | 1 | 0 | 0
|
| 2 | ACHILLES | 1 | 0 | 0
|
| 3 | ACRIDONES | 1 | 0 | 0
|
| 4 | ACTION | 2 | 3 | 15
|
| 5 | ACTIVATION | 4 | 5 | 6
|
| 6 | ACTIVITIES | 1 | 0 | 0
|
| 7 | ACTIVITY | 3 | 0 | 0
|
| 8 | ADAPTIVE | 1 | 0 | 0
|
| 9 | ADAPTOR | 1 | 6 | 41
|
| 10 | ADVANCES | 1 | 0 | 1
|
| 11 | AGENTS | 1 | 0 | 0
|
| 12 | ALPHA | 1 | 0 | 0
|
| 13 | ALPHA-GLUCOSIDASE | 1 | 0 | 0
|
| 14 | ANALYSES | 1 | 0 | 0
|
| 15 | ANALYSIS | 3 | 1 | 4
|
| 16 | ANTI-BVDV | 1 | 0 | 0
|
| 17 | ANTI-HCV | 1 | 0 | 0
|
| 18 | ANTI-HEPATITIS | 1 | 1 | 1
|
| 19 | ANTIBODIES | 1 | 0 | 0
|
| 20 | ANTIBODY | 1 | 0 | 0
|
| 21 | ANTIVIRAL | 7 | 6 | 42
|
| 22 | APOB-CONTAINING | 1 | 0 | 0
|
| 23 | APOLIPOPROTEIN | 1 | 0 | 0
|
| 24 | APOPTOSIS | 1 | 1 | 2
|
| 25 | APPROACH | 1 | 0 | 0
|
| 26 | APPROACHES | 1 | 0 | 0
|
| 27 | ASSAY | 1 | 0 | 0
|
| 28 | ASSEMBLY | 2 | 1 | 2
|
| 29 | BACULOVIRUS | 1 | 0 | 0
|
| 30 | BILIARY | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 31 | BINDING | 2 | 0 | 0
|
| 32 | BIOLOGICAL | 2 | 0 | 1
|
| 33 | BROADLY | 1 | 0 | 0
|
| 34 | CAPTURING | 1 | 0 | 0
|
| 35 | CARCINOMA | 1 | 0 | 0
|
| 36 | CARDIF | 1 | 6 | 41
|
| 37 | CDNA-TRANSFECTED | 1 | 2 | 2
|
| 38 | CELL | 10 | 78 | 79
|
| 39 | CELL-CELL | 1 | 0 | 0
|
| 40 | CELLS | 8 | 4 | 4
|
| 41 | CHARACTERIZATION | 4 | 0 | 0
|
| 42 | CHIMERAS | 1 | 0 | 0
|
| 43 | CHRONIC | 1 | 0 | 0
|
| 44 | CIRCLE | 1 | 1 | 2
|
| 45 | CLA | 1 | 0 | 0
|
| 46 | CLATHRIN-MEDIATED | 1 | 0 | 0
|
| 47 | CLEAVAGE | 2 | 0 | 0
|
| 48 | CLINICAL | 1 | 0 | 1
|
| 49 | COMBINATION | 1 | 0 | 0
|
| 50 | COMPLETE | 1 | 74 | 74
|
| 51 | COMPLEX | 1 | 1 | 4
|
| 52 | CONCOMITANT | 1 | 1 | 2
|
| 53 | CONFLUENCE-BASED | 1 | 0 | 1
|
| 54 | CONSTRUCTION | 1 | 0 | 0
|
| 55 | CORE | 1 | 0 | 0
|
| 56 | CORE-RNA | 1 | 0 | 0
|
| 57 | COUNTERS | 1 | 0 | 2
|
| 58 | CULTURE | 4 | 76 | 77
|
| 59 | CULTURE-GROWN | 1 | 2 | 2
|
| 60 | CULTURED | 1 | 1 | 1
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 61 | CULTURES | 1 | 0 | 0
|
| 62 | CYCLOSPORIN | 1 | 0 | 0
|
| 63 | CYCLOSPORINE | 1 | 0 | 0
|
| 64 | CYTOSKELETON | 1 | 0 | 0
|
| 65 | DC-SIGN | 1 | 0 | 0
|
| 66 | DC-SIGNR | 1 | 0 | 0
|
| 67 | DEBIO | 1 | 0 | 0
|
| 68 | DEFINED | 1 | 0 | 0
|
| 69 | DELETION | 1 | 0 | 0
|
| 70 | DENSITY | 1 | 0 | 0
|
| 71 | DEPENDS | 1 | 0 | 0
|
| 72 | DETECTION | 1 | 1 | 1
|
| 73 | DEVELOPMENT | 1 | 0 | 1
|
| 74 | DIFFERENT | 2 | 0 | 0
|
| 75 | DIHYDROXY-4-CARBOXYPYRIMIDINES | 1 | 0 | 0
|
| 76 | DIMERIZATION | 1 | 0 | 0
|
| 77 | DIRECT | 1 | 0 | 0
|
| 78 | DISCOVERY | 2 | 0 | 0
|
| 79 | DISORDERS | 2 | 1 | 2
|
| 80 | DISPENSABLE | 1 | 0 | 0
|
| 81 | DISTINCT | 3 | 0 | 0
|
| 82 | DIVERSE | 1 | 0 | 0
|
| 83 | DOMAINS | 1 | 0 | 0
|
| 84 | DRUG | 1 | 0 | 1
|
| 85 | DSRNA-INDUCED | 1 | 0 | 0
|
| 86 | EARLY | 1 | 0 | 0
|
| 87 | EFFECT | 3 | 0 | 1
|
| 88 | EFFECTS | 3 | 1 | 3
|
| 89 | EFFICIENTLY | 1 | 1 | 1
|
| 90 | EMPIRICISM | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 91 | ENDOCYTOSIS | 1 | 0 | 0
|
| 92 | ENDOTHELIAL | 1 | 0 | 0
|
| 93 | ENDOTHELIUM | 1 | 0 | 0
|
| 94 | ENGAGEMENT | 1 | 0 | 0
|
| 95 | ENHANCES | 1 | 0 | 0
|
| 96 | ENTRY | 6 | 5 | 5
|
| 97 | ENVELOPE | 1 | 0 | 0
|
| 98 | EPITOPE | 1 | 0 | 0
|
| 99 | ERADICATION | 1 | 0 | 0
|
| 100 | ESCAPE | 1 | 0 | 0
|
| 101 | EXHIBITS | 1 | 0 | 0
|
| 102 | EXPRESSION | 4 | 0 | 1
|
| 103 | FACE | 1 | 0 | 1
|
| 104 | FEATURES | 1 | 1 | 1
|
| 105 | FULL | 1 | 1 | 2
|
| 106 | FULLY | 1 | 0 | 0
|
| 107 | FUNCTION | 2 | 7 | 15
|
| 108 | FUNCTIONAL | 2 | 1 | 2
|
| 109 | FUNCTIONS | 1 | 0 | 0
|
| 110 | FUSION | 2 | 3 | 3
|
| 111 | FUTURE | 1 | 0 | 1
|
| 112 | GENERATED | 1 | 0 | 0
|
| 113 | GENERATION | 1 | 0 | 0
|
| 114 | GENOME | 2 | 7 | 15
|
| 115 | GENOTYPE | 1 | 1 | 1
|
| 116 | GLYCOPROTEINS | 2 | 4 | 5
|
| 117 | GROW | 1 | 0 | 0
|
| 118 | GROWTH | 1 | 0 | 1
|
| 119 | HAIRPIN | 1 | 0 | 0
|
| 120 | HCV | 6 | 2 | 3
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 121 | HCV-LIKE | 2 | 0 | 0
|
| 122 | HEEL | 1 | 0 | 0
|
| 123 | HELICASES | 1 | 0 | 0
|
| 124 | HEPATITIS | 56 | 114 | 191
|
| 125 | HEPATOCELLULAR | 1 | 0 | 0
|
| 126 | HEPATOCYTES | 2 | 0 | 0
|
| 127 | HEPATOMA | 4 | 4 | 4
|
| 128 | HIGH | 1 | 0 | 0
|
| 129 | HIGHLY | 1 | 1 | 1
|
| 130 | HORSE | 1 | 0 | 0
|
| 131 | HOST | 1 | 0 | 0
|
| 132 | HUMAN | 8 | 4 | 4
|
| 133 | HUTCHINSON | 1 | 1 | 1
|
| 134 | IDENTIFY | 1 | 0 | 0
|
| 135 | IMMORTALIZED | 1 | 0 | 0
|
| 136 | IMMUNE | 1 | 0 | 0
|
| 137 | IMMUNITY | 1 | 0 | 2
|
| 138 | IMPLICATION | 1 | 0 | 0
|
| 139 | INCORPORATION | 1 | 1 | 2
|
| 140 | INDEPENDENT | 1 | 0 | 0
|
| 141 | INDUCED | 2 | 0 | 0
|
| 142 | INFECTION | 2 | 0 | 0
|
| 143 | INFECTIOUS | 7 | 7 | 9
|
| 144 | INHIBIT | 1 | 0 | 0
|
| 145 | INHIBITION | 2 | 0 | 1
|
| 146 | INHIBITOR | 5 | 1 | 1
|
| 147 | INHIBITORS | 2 | 0 | 0
|
| 148 | INHIBITS | 3 | 2 | 3
|
| 149 | INNATE | 2 | 0 | 2
|
| 150 | INSERTION | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 151 | INSIGHTS | 1 | 0 | 0
|
| 152 | INTERACTION | 2 | 0 | 0
|
| 153 | INTERACTIONS | 2 | 3 | 9
|
| 154 | INTERFERENCE-MEDIATED | 1 | 0 | 0
|
| 155 | INTERFERING | 1 | 0 | 2
|
| 156 | INTERFERON | 4 | 4 | 16
|
| 157 | INTERFERONS | 1 | 0 | 2
|
| 158 | INTERGENOTYPIC | 1 | 0 | 0
|
| 159 | INTERNAL | 1 | 0 | 0
|
| 160 | INTRACELLULAR | 1 | 0 | 0
|
| 161 | INTRACELLULARLY | 1 | 1 | 2
|
| 162 | INTRAGENOTYPIC | 1 | 0 | 0
|
| 163 | KETOAMIDE | 1 | 0 | 0
|
| 164 | LDL-R | 1 | 0 | 0
|
| 165 | LINE | 1 | 0 | 0
|
| 166 | LIPOPROTEIN | 2 | 1 | 1
|
| 167 | LIPOPROTEINS | 2 | 0 | 0
|
| 168 | LIPOSOMES | 1 | 3 | 3
|
| 169 | LIVER | 3 | 0 | 0
|
| 170 | LOCALIZATION | 1 | 1 | 1
|
| 171 | LOW | 1 | 3 | 3
|
| 172 | LOW-DENSITY | 1 | 1 | 1
|
| 173 | LOW-PH-TRIGGERED | 1 | 4 | 4
|
| 174 | LUCIFERASE | 2 | 0 | 0
|
| 175 | LYMPHOCYTE | 1 | 1 | 2
|
| 176 | LYMPHOCYTES | 1 | 1 | 2
|
| 177 | MATURATION | 1 | 0 | 0
|
| 178 | MEASUREMENT | 1 | 0 | 0
|
| 179 | MECHANISM | 3 | 4 | 18
|
| 180 | MECHANISM-BASED | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 181 | MECHANISMS | 2 | 0 | 0
|
| 182 | MEDIATE | 2 | 3 | 3
|
| 183 | MEDIATED | 1 | 0 | 0
|
| 184 | MEMBRANE | 1 | 3 | 3
|
| 185 | MEMBRANES | 1 | 0 | 0
|
| 186 | MENACE | 1 | 0 | 0
|
| 187 | MILESTONE | 1 | 0 | 0
|
| 188 | MODELING | 1 | 0 | 0
|
| 189 | MODULATES | 1 | 0 | 0
|
| 190 | MOLECULAR | 3 | 1 | 1
|
| 191 | MONOCLONAL | 1 | 0 | 0
|
| 192 | MORPHOGENESIS | 1 | 0 | 0
|
| 193 | MOVE | 1 | 0 | 0
|
| 194 | MUTAGENESIS | 1 | 0 | 0
|
| 195 | MUTAGENIC | 1 | 0 | 2
|
| 196 | NAIVE | 1 | 1 | 2
|
| 197 | NATURAL | 1 | 0 | 0
|
| 198 | NEUTRALIZING | 1 | 0 | 0
|
| 199 | NEW | 3 | 0 | 0
|
| 200 | NON-IMMUNOSUPPRESSIVE | 1 | 0 | 0
|
Page 1 of 2: [ 1 2 ]